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Abstract
Background: Human African trypanosomiasis (HAT), also known as sleeping sickness, is a fatal parasitic disease caused by
trypanosomes. Current treatment options for HAT are scarce, toxic, no longer effective, or very difficult to administer, in
particular for the advanced, fatal stage of the disease (stage 2, chronic HAT). New safe, effective and easy-to-use treatments
are urgently needed. Here it is shown that fexinidazole, a 2-substituted 5-nitroimidazole rediscovered by the Drugs for
Neglected Diseases initiative (DNDi) after extensive compound mining efforts of more than 700 new and existing
nitroheterocycles, could be a short-course, safe and effective oral treatment curing both acute and chronic HAT and that
could be implemented at the primary health care level. To complete the preclinical development and meet the regulatory
requirements before initiating human trials, the anti-parasitic properties and the pharmacokinetic, metabolic and
toxicological profile of fexinidazole have been assessed.
Methods and Findings: Standard in vitro and in vivo anti-parasitic activity assays were conducted to assess drug efficacy in
experimental models for HAT. In parallel, a full range of preclinical pharmacology and safety studies, as required by
international regulatory guidelines before initiating human studies, have been conducted. Fexinidazole is moderately active
in vitro against African trypanosomes (IC50 against laboratory strains and recent clinical isolates ranged between 0.16 and
0.93 mg/mL) and oral administration of fexinidazole at doses of 100 mg/kg/day for 4 days or 200 mg/kg/day for 5 days
cured mice with acute and chronic infection respectively, the latter being a model for the advanced and fatal stage of the
disease when parasites have disseminated into the brain. In laboratory animals, fexinidazole is well absorbed after oral
administration and readily distributes throughout the body, including the brain. The absolute bioavailability of oral
fexinidazole was 41% in mice, 30% in rats, and 10% in dogs. Furthermore, fexinidazole is rapidly metabolised in vivo to at
least two biologically active metabolites (a sulfoxide and a sulfone derivative) that likely account for a significant portion of
the therapeutic effect. Key pharmacokinetic parameter after oral absorption in mice for fexinidazole and its sulfoxide and
sulfone metabolites are a Cmax of 500, 14171 and 13651 ng/mL respectively, and an AUC0–24 of 424, 45031 and 96286 h.ng/
mL respectively. Essentially similar PK profiles were observed in rats and dogs. Toxicology studies (including safety
pharmacology and 4-weeks repeated-dose toxicokinetics in rat and dog) have shown that fexinidazole is well tolerated. The
No Observed Adverse Event Levels in the 4-weeks repeated dose toxicity studies in rats and dogs was 200 mg/kg/day in
both species, with no issues of concern identified for doses up to 800 mg/kg/day. While fexinidazole, like many
nitroheterocycles, is mutagenic in the Ames test due to bacterial specific metabolism, it is not genotoxic to mammalian cells
in vitro or in vivo as assessed in an in vitro micronucleus test on human lymphocytes, an in vivo mouse bone marrow
micronucleus test, and an ex vivo unscheduled DNA synthesis test in rats.
Conclusions: The results of the preclinical pharmacological and safety studies indicate that fexinidazole is a safe and
effective oral drug candidate with no untoward effects that would preclude evaluation in man. The drug has entered first-in-
human phase I studies in September 2009. Fexinidazole is the first new clinical drug candidate with the potential for
treating advanced-stage sleeping sickness in thirty years.
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A major challenge for new drug development is the identifica-
tion of pharmacologically active compounds with a favourable
activity and toxicity profile that can be turned into new drug
candidates. The contemporary approach to identifying such
compounds is high-throughput screening of large and chemically
diverse compound libraries to identify novel pharmacophores,
followed by lead optimisation [1,2]. Sometimes, this screening
effort is narrowed down by using more targeted libraries that are
thought to be enriched in compounds with a desired type of
activity (e.g. kinase inhibitors [3]). However, promising candidates
can also be found by revisiting the wealth of past drug discovery
research, during which promising lines of research were sometimes
not pursued for commercial or other strategic reasons.
In this paper, we report the successful result of a proactive
compound mining approach into a well-known class of anti-
infectives, the nitroimidazoles, to rediscover fexinidazole, a long
forgotten antiparasitic drug candidate. Fexinidazole turned out to
be an excellent candidate to cure human African trypanosomiasis
(HAT), including the advanced and fatal stage of the disease.
An estimated sixty million people in 36 sub-Saharan African
countries are at risk for HAT, especially poor and neglected
populations living in remote rural areas [4,5]. While the number of
reported HAT cases has decreased in recent years due to
intensified control activities, 50,000 to 70,000 people are estimated
to be infected [6]. In west and central Africa, Trypanosoma brucei
gambiense causes a chronic form of sleeping sickness, whereas in
eastern and southern Africa T. b. rhodesiense causes an acute form of
the disease [7,8]. Both forms of HAT occur in two stages: stage 1
(early, hemolymphatic) is characterized by non-specific clinical
symptoms such as malaise, headache, fever, and peripheral
oedema, whereas stage 2 (late, meningoencephalic) is character-
ized by neurological symptoms including behavioural changes,
severe sleeping disturbances, and convulsions, which, if left
untreated, lead to coma and death [9,10].
Available treatments for HAT [8] (Table 1) are few, old, and
limited due to toxicity, diminishing efficacy in several geographical
regions [11,12], and complexity of use [13]. Treatment is stage-
specific, with the more toxic and difficult-to-use treatments being
used for stage 2 HAT.
NECT, a combination treatment of a simplified course of
intravenous eflornithine and oral nifurtimox, has been the only
advance in the past 25 years [14,15], and has been recently
accepted into the WHO’s Essential Medicines List as treatment for
stage 2 HAT [16]. Despite being a clear improvement with
reduced toxicity and treatment duration, the requirement for
intravenous administration is still a limitation.
It is estimated that less than 20% of currently infected people
have access to treatment or are under any HAT surveillance, due
to a combination of lack of effective and field-adapted diagnostics
and treatments, combined with extreme poverty and remoteness of
the affected populations, including in conflict zones [4,17]. To
change the dynamics of HAT control and access more patients
while improving their case-management, a safe, effective,
affordable, and easy-to-use (short course, preferably oral) treat-
ment is urgently needed.
Nitroimidazoles are a well-known class of pharmacologically
active compounds, among which several have shown good activity
against trypanosomes [18]. The best-known anti-trypanosomal
drug candidate in this class was megazol [19,20]; its development
was abandoned because of toxicity, in particular mutagenicity
[21,22], a known possibility in this chemical family [23,24].
However, other members of this family including metronidazole
[25], are widely used as antibiotics, indicating that it is possible to
select compounds with an acceptable activity/toxicity profile in
this class.
A systematic review and profiling of more than 700 nitroheter-
ocyclic compounds (mostly nitroimidazoles) from diverse sources
was undertaken and included an assessment of antiparasitic
activity and mutagenic potential using state-of-the-art scientific
methods. From these efforts, fexinidazole, a 2-substituted 5-
nitroimidazole, was identified as a promising drug candidate for
the treatment of HAT. Fexinidazole (1-methyl-2-((p-(methylthio)-
Table 1. Available treatment options for HAT.
Indication Drug Associated Problems
Stage 1 Pentamidine (1940) 7–10 daily intramuscular injections; only efficacious for stage 1
Suramin (1920’s) Used primarily for stage 1 T. b. rhodesiense HAT
Stage 2 Melarsoprol (1949) Ten painful daily intravenous injections; highly toxic, with ,5 % treatment-related mortality. Increasing number of
treatment failures (up to 30% in some regions); used for stage 2 HAT
Eflornithine (1981) Administration difficult – 4 slow intravenous infusions per day for 14 days; increasingly used as 1st line for T. b.
gambiense stage 2 HAT
NECT
(2009)
Simplified regimen combining 7 days eflornithine (two infusions/day) and 10 days oral nifurtimox; expected to
replace eflornithine monotherapy and melarsoprol for stage 2 T. b. gambiense HAT
doi:10.1371/journal.pntd.0000923.t001
Author Summary
This article describes the preclinical profile of fexinidazole,
a new drug candidate with the potential to become a
novel, oral, safe and effective short-course treatment for
curing both stage 1 and 2 human African trypanosomiasis
and replace the old and highly problematic treatment
modalities available today. Fexinidazole is orally available
and rapidly metabolized in two metabolites having
equivalent biological activity to the parent and contribut-
ing significantly to the in vivo efficacy in animal models of
both stage 1 and 2 HAT. Animal toxicology studies indicate
that fexinidazole has an excellent safety profile, with no
particular issues identified. Fexinidazole is a 5-nitroimida-
zole and, whilst it is Ames-positive, it is devoid of any
genetic toxicity in mammalian cells and therefore does not
pose a genotoxic risk for use in man. Fexinidazole, which
was rediscovered through a process of compound mining,
is the first new drug candidate for stage 2 HAT having
entered clinical trials in thirty years, and has the potential
to revolutionize therapy of this fatal disease at a cost that
is acceptable in the endemic regions.
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37-2) had been in preclinical development in the 1970s and early
1980s as a broad-spectrum antimicrobial agent by Hoechst AG
(now sanofi-aventis), selected within a broader series because of its
wider range of action, lower toxicity and comparative ease of
chemical synthesis [26,27]. In 1983, the in vivo activity of
fexinidazole against African trypanosomes was further substanti-
ated [28]. However, fexinidazole’s development was not pursued
at the time.
This paper describes the trypanocidal efficacy and preclinical
profile of fexinidazole as a novel clinical drug candidate for HAT,
devoid of genotoxic risks for patients. The results show
fexinidazole’s potential to become a safe, efficacious, affordable,
short-course (less than 14 days), oral treatment with a suitable shelf
life in tropical conditions. Ideally the treatment will be safe and
effective in both stages 1 and 2 HAT caused by T. b. gambiense and
T. b. rhodesiense, allowing for significantly simplified diagnosis,
treatment and patient-management and ultimately a better control
of the disease.
Methods
Ethics Statement
All work was conducted in accredited laboratories and
according to international guidelines. Specific references to the
relevant authorities are provided below as appropriate. Where not
stated, details of specific license holders can be obtained from the
appropriate laboratories if required.
Drug preparation
Fexinidazole and metabolites were prepared for in vitro studies as
a stock solution in DMSO further diluted with water or 0.5%
methylcellulose in water to appropriate concentration required for
the assay.
For in vivo studies, fexinidazole was prepared as an optimized
suspension comprising 5% w/v Tween 80/0.5% w/v Methocel in
water, unless stated otherwise.
Anti-trypanosomal activity studies
In vitro trypanocidal and cytotoxicity assays
[29,30,31]. Parasites were cultured with or without the test
article at a concentration of 3610
4/mL in Minimal Essential
Medium, according to Baltz et al. [30], with the following
modifications: 0.2 mM 2-mercaptoethanol, 1 mM Na-pyruvate,
0.5 mM hypoxanthine and 15% heat inactivated horse serum at
37uCi n5 %C O 2 in 96-well microtitre plates for 72 h. 10 mLo f
Alamar Blue was added for the final 3 h to determine viability.
The assay was assessed by reading the fluorescence in each well at
an excitation wavelength of 536 nm and at an emission
wavelength of 588 nm. The IC50 values were calculated from
the sigmoidal inhibition curves. For cytotoxicity, 4610
4/mL L-6
rat skeletal myoblast cells were used, and incubations and
assessments carried out as above.
In vivo trypanocidal assays [32,33]. Female NMRI mice
were infected via intraperitoneal injection with bloodstream forms
of T. b. rhodesiense STIB900 or T. b. gambiense 130R and treated with
test drugs daily for 4 consecutive days, starting on day 3 or 7 after
infection, respectively, or with bloodstream forms of T. b brucei
GVR35 and treated daily from day 21 after infection for 5 days.
Parasitemia was evaluated by tail blood examination and
surviving, aparasitaemic mice at 60, 90, or 180 days, respect-
ively, were considered cured.
The mouse assays were conducted in accordance to relevant
national and international guidelines. The studies were approved
by the local veterinary office (Kantonales Veterina ¨ramt Basel)
under licence No. 739.
Pharmacokinetic (PK) studies
A range of pharmacokinetic studies have been performed in
different species (mouse, rat, dog) in the context of this paper,
either as pharmacokinetic studies to establish the PK profile of
fexinidazole and its metabolites, or as part of other studies (safety
pharmacology and toxicity) to demonstrate the systemic exposure
of fexinidazole and its metabolites in the conditions of that
particular study.
Plasma sampling. Blood samples were taken via into he-
parinised collection tubes and, following centrifugation, plasma
was removed and stored frozen until required for assay.
Brain sampling in mice. Following sacrifice, the cranium of
mice was opened and the brain removed. Excess blood was
washed from the brain with distilled water and any excess fluid
blotted on absorbent paper. The brain was then snap frozen using
liquid nitrogen and placed into a suitably labelled container and
stored at approximately 270uC, pending analysis. Brains were
homogenized and extracted samples were prepared appropriately
for analysis via liquid chromatography-mass spectrometry (LC-
MS).
Plasma and brain pharmacokinetic (PK) analytical
assessment. All PK evaluations were carried out using
validated high performance liquid chromatography (HPLC) and
LC-MS assays, as per standard operating procedures of the
laboratories involved.
The majority of PK studies were carried out by Accelera,
Nerviano Medical Sciences, Italy, following internal Standard
Operating Procedures as non-GLP regulated studies, and all
procedures for housing and handling of animals were in strict
compliance with EEC and Italian Guidelines for Laboratory
Animal Welfare.
One mouse PK and brain sampling study was carried out by
BioDynamics Ltd., Rushden, UK, according to internal Standard
Operating Procedures as a non-GLP regulated study, and animals
were maintained as required by the ‘‘Code of practice for the
housing and care of animals used in scientific procedures’’ (Home
Office, London, 1989).
ADME (Absorption, Distribution, Metabolism, Excretion)
studies
In vitro hepatocyte metabolism [34]. Fexinidazole was
incubated with cryopreserved hepatocytes from male CD-1 mice,
male Sprague Dawley rats, male beagle dogs, male cynomolgus
monkeys, and from pooled white or African-American human
donor samples (purchased commercially), at concentrations of
1 mM and 10 mM. 1 mM samples were used for the cross-species
intrinsic clearance determination, whereas 10 mM samples were
used for the cross-species metabolite profile determination. The
incubated samples were analyzed by LC-MS after extraction into
acetonitrile.
In vitro CYP-450 metabolism [35]. Duplicate samples of
human recombinant CYP enzyme isotypes CYP1A2, CYP2B6,
CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5
(10–30 pmol/mL) with NADPH as cofactor were incubated with
fexinidazole, fexinidazole sulfoxide, or fexinidazole sulfone at a
concentration of 1.0 mM for up to 60 min (pH 7.4, 37uC).
Detection of the compounds was via HPLC-MS.
In vitro transcellular permeability. Caco-2 [36] or
MDR1-MDCK (Madin Darby canine kidney cells transfected
with the human multidrug resistance MDR1 gene) [37] cell
monolayers were grown to confluence on collagen-coated,
Fexinidazole for Sleeping Sickness
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plates. The buffer for the donor chamber was Hanks balanced salt
solution with 10 mM HEPES and 15 mM glucose at pH 7.4. The
buffer in the receiver chamber contained the same with the
addition of 1% bovine serum albumin (BSA). The test article was
added at 5 mM in the assay buffer. Cells were dosed on the apical
side or baso-lateral side and incubated at 37uC with 5% CO2 in a
humidified incubator. After 2 h, duplicate aliquots were taken
from the donor and receiver chambers and assayed via LC/MS.
The apparent permeability and recovery were calculated using
standard methods.
In vivo metabolism and distribution. Whole-body
autoradiography in rats was conducted using [
14C]-radiolabelled
fexinidazole. The site of the [
14C] label in the fexinidazole
molecule on the bridging carbon atom ensured that the
radioactivity would remain associated with both the sulfoxide
and sulfone metabolites. The radiolabelled compound was
administered at the dose of 800 mg/kg (approximately
3.7 MBq/kg, 100 mCi/kg) by gastric gavage to eight male albino
Sprague Dawley rats. Two animals were sacrificed at each time
point 2, 8, 24 or 48 h after administration and the quantitative
radioactivity distribution in the organs and tissues was evaluated
using quantitative whole-body autoradiography.
Excretion balance in rats was carried out using a single oral dose
of radiolabelled fexinidazole administered at the dose of 800 mg/
kg (approximately 3.7 MBq/kg, 100 mCi/kg) by gastric gavage to
three male albino Sprague Dawley rats.
The animal studies above were carried out by Accelera,
Nerviano Medical Sciences, Italy, following internal Standard
Operating Procedures as non-GLP regulated studies, and all
procedures for housing and handling of animals were in strict
compliance with EEC and Italian Guidelines for Laboratory
Animal Welfare.
Safety pharmacology profiling [38,39]
In vitro cardiac safety [40]. HEK 293 (human embryonic
kidney) cells stably expressing hERG (human ether-a-go-go-related
gene) were treated with fexinidazole, fexinidazole sulfoxide, or
fexinidazole sulfone at 1, 5 or 30 mM, and the hERG peak tail
current was measured.
In vivo cardiovascular safety assessment [40]. Cardi-
ovascular safety parameters were assessed in beagle dogs. Four
adult (.1 year old) beagle dogs were given oral doses of
fexinidazole at 100, 300 and 1000 mg/kg in an escalating dose
design. During the experimental phase, animals were monitored
via a Closed Circuit TeleVision (CCTV) system and physically
inspected 24 h after dosing. On the day of dosing, a predefined set
of telemetry signals from each animal were collected continuously
from at least 1 h before dosing to at least 24 h after treatment.
In vivo neurobehavioural safety profiling. Neuro-
behavioural safety was carried out using the Irwin’s test of general
behaviour and body temperature in male rats [39,41]. Twenty-four
malerats(Crl:CD(SD)BR),agedabout7 weeksonthedayofdosing,
were divided into four experimental groups of 6 animals per group.
Each group of animals was treated orally with fexinidazole at doses
of 100, 300, or 1000 mg/kg, or vehicle. General behaviour was
assessed before treatment and 2 h and 24 h after vehicle or drug
administration. A defined set of behavioural observations using an
arbitrary intensity scale of 0 (no behavioural change) to 8 was made
before treatment and 2 h and 24 h after treatment. Factors present
in normal animals (e.g. alertness, mobility) were scored as 4;
potentiation ordepressionof thesefactors was indicatedas higheror
lower integers, respectively. Factors absent in normal animals were
scored from 0 (normal) to 8.
In vivo respiratory safety profiling. Respiratory
parameters were assessed in the rat [42]. Groups of eight male
rats (Crl:CD(SD)BR), aged about 8 weeks on the day of dosing,
were administered doses of 100, 300, or 1000 mg/kg of
fexinidazole by oral gavage. A predetermined standard set of
respiratory parameters was acquired continuously from individual
animals housed in plethysmographic chambers. Basal values were
calculated as the mean of values from 30 to 10 min before
treatment. After treatment, values were extracted every 30 min up
to 4 h. Body weights were recorded on the day of treatment for
calculation of dose volumes and for calculation of tidal and minute
volumes per kg of body weight.
All safety pharmacology studies in animals were carried out by
Accelera, Nerviano Medical Sciences, Italy, following internal
Standard Operating Procedures and applicable ICH guidelines
(ICH S7A, S7B), were GLP regulated and were conducted in
compliance with the DECRETO LEGISLATIVO 2 Marzo 2007,
No. 50 and OECD Principles of GLP (January 1998) ENV/MC/
CHEM (98) 17.
Repeated–Dose Study/Toxicokinetics [43,44]
In the rat repeated-dose toxicokinetic study, fexinidazole was
administered orally by gavage once a day for 28 consecutive days
to ten or fifteen Crl:CD (SD)IGS BR rats/sex/group at doses of
50, 200, or 800 mg/kg/day. A control group received the vehicle
alone (5% Tween 80/0.5% methocel). Ten animals/sex/group
were sacrificed at the end of the treatment period on day 29 or 30
of study. The remaining 5 animals/sex/group in the control and
high-dose groups were sacrificed on day 43 at the end of a 2-weeks
observation period. Systemic exposure to fexinidazole and its
sulfoxide and sulfone metabolites was evaluated in three additional
animals/sex/group. Samples were taken at predose, and 30 min,
1, 2, 4, 8 and 24 h after dosing on days 1, 14, and 28, and in
addition at 48 and 72 h after treatment on day 28.
In the dog repeated-dose toxicokinetic study, fexinidazole was
given orally by gavage once a day for 28 days to five (control and
high dose) or three (low and mid dose) beagle dogs/sex/dose at the
doses of 0 (control group), 50, 200, or 800 mg/kg/day. The
control group received the vehicle alone (same as above). Systemic
exposure to fexinidazole and of its sulfoxide and sulfone
metabolites was evaluated on days 1, 14 and 28 in the same
animals used for the toxicological study. Samples were taken at
predose, and 30 min, 1, 2, 4, 8 and 24 h after dosing on days 1,
14, and 28, and in addition at 48 and 72 h after treatment on day
28.
For both species, the standard package of toxicological analyses
was carried out.
Both rat and dog studies were carried out by Accelera, Nerviano
Medical Sciences, Italy, according to their internal Standard
Operating Procedures, were GLP regulated and were conducted
in compliance with the DECRETO LEGISLATIVO 2 Marzo
2007, No. 50 and OECD Principles of GLP (January 1998) ENV/
MC/CHEM (98) 17 and the ICH regulatory guidelines for
repeated-dose toxicokinetics studies (ICH M3 and S3A).
Developmental and reproductive toxicology [45]
Preliminary studies in rat and rabbit have been performed to
have an early idea of reproductive and developmental toxicity
risks, and to determine dose levels to be used in further pivotal
studies.
In the rat study, fexinidazole was administered orally by gavage
once a day from day 6 to day 17 of gestation or from day 6 of
gestation to day 7 of lactation to 10 mated rat Crl:CD (SD)IGS BR
Fexinidazole for Sleeping Sickness
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group received the vehicle alone (5% Tween 80/0.5% methocel).
In the rabbit study, fexinidazole was administered orally by
gavage once a day from day 6 to day 20 of gestation to 6
inseminated New Zealand White Rabbit KBL females at the dose
of 20, 40 and 80 mg/kg/day. A control group received the vehicle
alone (5% Tween 80/0.5% methocel).
Both rat and rabbit studies were carried out by Accelera,
Nerviano Medical Sciences, Italy, according to their internal
Standard Operating Procedures, were GLP regulated and were
conducted in compliance with the DECRETO LEGISLATIVO 2
Marzo 2007, No. 50 and OECD Principles of GLP (January 1998)
ENV/MC/CHEM (98) 17 and the appropriate ICH regulatory
guidelines for reproductive toxicology (ICH S5A).
Genotoxicity assessments [46]
In vitro Ames test. To evaluate bacterial mutagenicity, a full
Ames test was carried out on fexinidazole and fexinidazole sulfone
using the five strains of Salmonella typhimurium recommended by the
relevant ICH regulatory guideline, namely TA1535, TA1537,
TA98, TA100, and TA102, as well as the corresponding
nitroreductase-deficient strains [47,48]. Standard bacterial plate
incorporation assays were carried out, essentially as described by
Maron and Ames [49]. Tests on fexinidazole were carried out with
and without rat liver post-mitochondrial fraction plus co-factors
(S9 mix) to provide a mammalian metabolic activation system.
The S9 fraction was prepared from Spague-Dawley rats pretreated
with the mixed cytochrome P 450 enzyme inducer Aroclor 1254.
Tests on fexinidazole sulfone were carried out only in the absence
of rat liver S9 (as this is a metabolite). After incubation at 37uC for
three days, plates were scored for mutant colonies using a Colony
Counter plate reader.
In vitro micronucleus test on human lymphocytes
[50]. Duplicate human lymphocyte cultures were prepared
from the pooled blood of two donors in two independent
experiments. Treatments covering a broad range of
concentrations, separated by narrow intervals, were done both
in the absence and presence of metabolic activation (S9) from
Aroclor-1254-induced animals. The highest concentration of
fexinidazole was 220 mg/mL. Cells were treated with the drug
either 24 h or 48 h after mitogen stimulation by
phytohaemagglutinin (PHA). The test concentrations for
micronucleus analysis were selected by evaluating the effect of
fexinidazole on the replication index (RI). In each experiment,
micronuclei were analysed at three concentrations. Similar tests
were carried out on fexinidazole sulfone. As per the Ames test, this
was carried out in the absence of rat liver S9 only.
In vivo mouse bone marrow micronucleus test
[51]. Groups of six young adult male Crl:CD-1 (ICR) mice
were treated with fexinidazole at two oral doses of 0, 500, 1000, or
2000 mg/kg given 24 h apart, and bone marrows were harvested
24 h after the second dose. Slides of bone marrow cells were
prepared, Giemsa stained, and 2000 polychromatic erythrocytes
per animal were scored for micronuclei.
Ex vivo unscheduled DNA synthesis (UDS) in rats
[52]. Groups of young male Sprague-Dawley rats received
fexinidazole at doses of 500, 1000, or 2000 mg/kg orally, and the
livers were sampled either 2–4 h or 12–14 h after administration.
Hepatocyte suspensions were prepared and incubated in the
presence of titrated thymidine. Slides of fixed hepatocytes were
coated in photographic emulsion and stored for 14 days at 4uCi n
the dark. The silver grains above the nuclei or cytoplasm
(background) were counted, providing a measure of DNA
uptake during DNA repair. The difference between these two
counts indicated the extent of DNA repair (nuclear net grain
count).
All genotoxicological studies in animals were carried out by
Covance Laboratories Ltd, Harrowgate, UK, following internal
Standard Operating Procedures, the applicable ICH guidelines
(ICH S2) and in compliance with the UK GLP Regulations 1999,
Statutory Instrument No. 3106 as amended by the GLP
(Codification Amendments Etc.) Regulations 2004 and the OECD
Principles on GLP (January 1998) ENV/MC/CHEM (98) 17.
Animals were maintained as required by the ‘‘Code of practice for
the housing and care of animals used in scientific procedures’’
(Home Office, London, 1989).
Redox potential measurement. One-electron reduction
potentials were determined by pulse radiolysis following an
established procedure [53].
Methods briefly described above are provided in full in the
supplementary data sets listed in the results section below.
Results
Antiparasitic activity
The antiparasitic activity of fexinidazole was assessed in
experimental models of HAT. In vitro fexinidazole and its two
main metabolites showed trypanocidal activity against the
STIB900 laboratory strain of T. b. rhodesiense with very steep
dose-response relations when assessed after 72 h of culture
(Figure 1). With an IC50 of 0.48–0.82 mg/mL, fexinidazole’s in
vitro potency is weaker than that of the reference drug melarsoprol
(IC50=0.003 mg/mL) and other trypanocidal drugs (Table 2) or
the abandoned drug candidate megazol (IC50=0.02 mg/mL),
although the two drugs currently used as first line to treat stage 2
HAT have a similarly modest in vitro potency (eflornithine: 0.9 mg/
mL; nifurtimox: 0.4 mg/mL). Importantly, in contrast to melar-
soprol and other drugs, fexinidazole has little or no non-specific
cytotoxicity. Fexinidazole has a comparable IC50 of 0.16–0.36 mg/
mL against a laboratory T. b. gambiense strain (STIB930) and
against six recent T. b. gambiense clinical isolates (IC50 values from
0.30 to 0.93 mg/mL) (data not shown).
In vivo, fexinidazole is effective in curing both T. b. rhodesiense and
T. b. gambiense acute models of infection at an oral dose of 100 mg/
kg/day (or 50 mg/kg twice a day) for 4 days (Table 3A). Most
significantly, in a T. b. brucei GVR35 infected mouse model of stage
2 HAT involving brain infection, fexinidazole given orally showed
a dose-related increase in efficacy, with a dose of 200 mg/kg/day
for 5 days being highly effective (Table 3B). In two other
independent experiments, 100% cure was obtained in groups of 5
mice receiving an oral dose of 100 mg/kg, twice per day for 5 days
(in these experiments, five daily intraperitoneal injections of
15 mg/kg melarsoprol also cured 100%). Of the drugs currently in
clinical use (Table 1), only melarsoprol is effective in this
experimental stage 2 HAT model.
ADME and pharmacokinetics (PK)
Fexinidazole is rapidly metabolised in vivo, with the main
metabolites being the sulfoxide and sulfone derivatives (Figure 2)
[26]. This principle metabolic conversion was confirmed in vitro
using rat S9 fractions and hepatocytes from the mouse, rat, dog,
monkey and human [Dataset S1]. In this comparative hepatocyte
metabolism assay, fexinidazole was rapidly metabolised by all
species, with in vitro intrinsic clearance rates highest in monkey
(6500 mL/min/kg) . dog (5000 mL/min/kg) . mouse
(4300 mL/min/kg) . rat (2900 mL/min/kg) . human
(125 mL/min/kg). No meaningful differences were observed
when comparing the in vitro metabolism of fexinidazole by
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S2]. The main metabolic pathways of oxidation to the sulfoxide
and sulfone derivatives were also confirmed to be the major route
of metabolism in vivo in mice, rats and dogs (see below). As shown
above, both metabolites have in vitro anti-trypanosomal activity
similar to the parent compound (IC50 in mg/mL: 0.41–0.49 for the
sulfoxide and 0.35–0.40 for the sulfone versus 0.48–0.82 for the
parent compound) (Table 2).
The potential hepatic oxidative pathways involved in fexinida-
zole metabolism were assessed by testing the clearance of the
fexinidazole and its two primary metabolites by a range of
cytochrome P450 (CYP450) enzymes [Dataset S3]. The data show
that fexinidazole is extensively metabolised by a range of CYP450
enzymes, including 1A2, 2B6, 2C19, 3A4, and 3A5 and, to a lesser
extent, 2D6. The 2C8 and 2C9 enzymes were inactive.
Interestingly, none of the enzymes tested metabolised either the
sulfoxide or the sulfone to any significant degree (their metabolic
pathways remain to be established). These data are in agreement
with in vivo data showing the long systemic half-lives of the
sulfoxide and sulfone metabolites in animal studies (see below).
Since fexinidazole is metabolised extensively by multiple CYP450
isoforms, its metabolism is unlikely to be significantly affected by
other drugs.
The oral absorption potential of fexinidazole was assessed in the
well-known Caco-2 cell model for intestinal epithelial permeability
[36, Dataset S4]. In this assay, fexinidazole showed high
absorption potential (apparent permeability Papp=57.2
10
26 cm/s and no significant efflux). Intestinal permeability of
fexinidazole is therefore not expected to be a limiting factor for
absorption in humans.
The PK profile of fexinidazole was assessed in single-dose and
multiple-dose studies in mice, rats and dogs. The absolute
bioavailability of oral fexinidazole was 41% in mice, 30% in rats,
and 10% in dogs. In all species tested, fexinidazole was rapidly and
extensively metabolised to the sulfoxide and subsequently sulfone
derivatives. Key pharmacokinetic parameters after oral absorption
Figure 1. Effect of fexinidazole and its two main metabolites on T. b. rhodesiense (STIB 900). Parasite viability was measured in vitro after
72-h drug exposure. Fexinidazole - open circles (n=11). Fexinidazole sulfoxide - open squares (n=4). Fexinidazole sulfone - open diamonds (n=4).
doi:10.1371/journal.pntd.0000923.g001
Table 2. In vitro anti-parasitic activity of fexinidazole, its metabolites, and reference compounds.
Compound
T. b. rhodesiense
(STIB 900)
T. b. gambiense
(STIB 930)
Cytotoxicity L-6 rat myoblast
cells
IC50 in mg/mL (mM)*
Fexinidazole 0.48–0.82 (1.71–2.93) 0.16–0.36 (0.58–1.29) .90 (.322)
Fexinidazole sulfoxide 0.41–0.49 (1.33–1.65) 0.18–0.36 (0.61–1.22) .90 (.305)
Fexinidazole sulfone 0.35–0.40 (1.14–1.30) 0.16–0.39 (0.48–1.25) .90 (.289)
Reference molecules
Melarsoprol 0.002–0.004 (0.004–0.009) 0.0015–0.003 (0.004–0.006) 1.3 (3.3)
Megazol 0.02 (0.10) Not available 57 (254)
Eflornithine 0.90 (3.80) 0.40 (1.67) 12 (51)
Nifurtimox 0.41 (1.44) 0.31 (1.08) 25 (87)
Pentamidine 0.003 (0.009) 0.002 (0.01) 3 (9)
Suramin 0.062 (0.046) Not available .90 (.70)
*IC50: concentration of drug required to kill 50% of the parasites or skeletal myoblast cells.
doi:10.1371/journal.pntd.0000923.t002
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Model Drug
Dose (mg/kg6No.
treatment days) Route* Cured/infected
Mean relapse time
(days)
A T. b. rhodesiense STIB900
(acute infection)
No treatment 0/4 7
Fexinidazole 2564 po 0/4 12
Fexinidazole 5064p o 1 / 4 .27
Fexinidazole 10064p o 4 / 4 .60
T. b. gambiense 130R
(acute infection)
No treatment 0/4 10
Fexinidazole 10064p o 3 / 3 .90
Melarsoprol 464i p 4 / 4 .90
B T. b. brucei
GVR35
(chronic infection)
Diminazene
+ 4061 ip 0/4 48.6
Fexinidazole 5065 po 0/8 41.3
Fexinidazole 10065p o 2 / 8 .82.1
Fexinidazole 20065p o 7 / 8 .163.8
Melarsoprol 1065i p 2 / 8 .96.6
Melarsoprol
++ 1565i p 4 / 5 .180
*ip: intraperitoneal; po: per os. Fexinidazole was formulated as a suspension in 5% Tween 80/95% methyl-cellulose (0.5% w/v in water) and administered via gastric
gavage.
+Diminazine diaceturate is used as a control as it is able to eliminate bloodstream parasitaemia but is not effective after CNS infection is established. Single dose on day
21 after infection.
++Data included from a separate experiment for illustration only.
doi:10.1371/journal.pntd.0000923.t003
Figure 2. Chemical structure of fexinidazole and its main metabolites [26], including
14C-labeled fexinidazole indicating which
carbon atom was labelled.
doi:10.1371/journal.pntd.0000923.g002
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are shown in Table 4 [Dataset S5]. Essentially similar PK profiles
were observed in rats and dogs [Datasets S6, S7], even if the exact
values varied among species (see also below).
The ability to cross the blood-brain barrier is crucial for drugs
intended to treat stage 2 HAT. The ability of fexinidazole to do so
was initially assessed in vitro in a MDR1-MDCK model [37,
Dataset S8]. Fexinidazole showed high predicted brain perme-
ation (apparent permeability Papp=60.6 10
26 cm/s and no
significant efflux). In mice, the presence of fexinidazole and both
metabolites in the brain was confirmed after oral dosing (Table 5,
Dataset S5), and is consistent with the data showing efficacy in the
murine model of chronic HAT (Table 3B).
The PK profile of fexinidazole was further characterised in mice
that were administered the same treatment schedule that was
curative in the chronic disease model (Table 3B). The plasma
profile in mice of fexinidazole and its sulfoxide and sulfone
metabolites after 5 days of fexinidazole treatment at the effective
dose (200 mg/kg/day) is illustrated in Figure 3. The data show
that a high and prolonged systemic bioavailability of biologically
active compounds is achieved a few hours after drug administra-
tion, seemingly without drug accumulation and associated
potential toxicity [Dataset S9].
This pattern of parent and metabolite plasma profiles without
significant drug accumulation is further illustrated in Tables 6 and
7, which show plasma PK parameters in Sprague-Dawley rats and
beagle dogs after 1 and 14 days of daily oral dosing with
fexinidazole (data taken from the 28-day toxicokinetics studies, see
below). In both species, it is interesting to note that there is no
apparent accumulation in the plasma of either parent drug or
metabolites, irrespective of dose, at least during the treatment
period of 1–14 days. In the dog, and to some extent in the rat, the
only difference seen between the data from day 1 versus day 14 is
that the Tmax for the sulfone metabolite occurs some hours earlier
on day 14 compared to day 1, although the overall amount of the
metabolite in plasma is similar on both days.
Whole-body autoradiography in rats using [
14C]-radiolabelled
fexinidazole (see figure 2 for labelling site) showed that the parent
drug and/or its metabolites are broadly distributed to all organs
and tissues (the assay did not distinguish between fexinidazole and
its metabolites), with peak concentrations in most tissues 2 h after
oral dosing. After 48 h, most radioactivity was eliminated from the
body and no tissue specific accumulation was noted [Dataset S10].
Furthermore, radioactivity was detected at all times in the brain,
with a brain-to-blood concentration ratio of 0.4–0.6.
Excretion balance studies in rats showed that 30% and 59% of
fexinidazole-related material was excreted via urine and faeces,
respectively, within 96 h [Dataset S11]. Elimination of the
radioactivity after oral dosing was rapid, with 84% eliminated
within 48 h. About 1.4% of the dose was recovered from the
carcass with an overall recovery of the total radioactivity of
approximately 93%.
Safety pharmacology
In regulatory safety pharmacology assessments, in vitro exposure
of hERG-transfected HEK 293 cells to fexinidazole sulfone, but
not fexinidazole or the sulfoxide, showed a statistically significant
decrease of 33% on hERG peak tail current at the highest of the
three doses tested (30 mM, 9.34 mg/mL; no effect at 1 or
5 mM)[Dataset S12]. However, assessment of cardiovascular
parameters in beagle dogs after single oral doses up to
1000 mg/kg showed no meaningful effects on blood pressure,
heart rate, and ECG intervals, including the Q-T interval [Dataset
S13]. Similarly, no meaningful effects were observed after single
oral doses in rats of up to 1000 mg/kg on general behaviour and
body temperature (modified Irwin’s test) or on respiratory
parameters [Datasets S14, S15].
Repeated-dose toxicity and reproductive toxicity
Because fexinidazole treatment for HAT is expected to be a
single regimen of 14 days or less, 28-day regulatory toxicokinetic
studies were carried out in rats and dogs.
Once daily oral fexinidazole doses of 50, 200 and 800 mg/kg/
day were well tolerated in rats at all doses tested [Dataset S16].
Only a minimal-to-slight decrease in food consumption and in the
expected body weight increases (due to normal growth) was
observed at 200 and 800 mg/kg, in male animals only. Minimal-
to-moderate changes were observed in the liver of all fexinidazole-
treated animals (increased liver weight and/or hypertrophy of the
centrilobular hepatocytes). However, there was no increase in liver
enzymes including AST and ALT, and all other clinical pathology
parameters were also normal. Taken together with the observation
that these changes were restricted to the dosing period, these were
considered of adaptive origin (metabolism) and not indicative for
liver toxicity. The No Observed Adverse Event Level (NOAEL) in
the rat was set at 200 mg/kg/day.
In Beagle dogs, daily oral fexinidazole doses of 50, 200 and
800 mg/kg/day were also well tolerated [Dataset S17]. Slight-to-
moderate body weight loss and reduction in food intake were
observed at 800 mg/kg/day during treatment. A minimal-to-slight
decrease in the number of lymphocytes was seen at the highest
dose. The No Observed Adverse Event Level (NOAEL) in the dog
was also set at 200 mg/kg/day.
Table 4. Mouse pharmacokinetics of fexinidazole and its
metabolites in plasma and brain after oral administration.
Cmax
(ng/mL)
Tmax
(h)
T1/2
(h)
AUC0–24
(ng.h/mL)
Fexinidazole 500 0.25 0.8 424
Sulfoxide metabolite 14171 0.5 1.0 45031
Sulfone metabolite 13651 4.0 1.7 96286
Fexinidazole was formulated as a suspension in 1% DMSO/99% methyl-cellulose
(1% w/v in water) and administered to female NMRI mice (n=3) via gastric
gavage at a concentration of 25 mg/kg.
Cmax: maximum plasma concentration. Tmax: time of maximum plasma
concentration. T1/2: terminal elimination half life. AUC0–24: area under curve
from time of dosing to the last measurable concentration.
doi:10.1371/journal.pntd.0000923.t004
Table 5. Presence of fexinidazole and metabolites in the
brain after oral administration of fexinidazole to mice.
Time point
(min)
Fexinidazole
(ng/g)
Sulfoxide
(ng/g)
Sulfone
(ng/g)
15 1136654.1 ND ND
30 800692.6 331561611 4696222
60 763690.7 487362335 11836322
Data are expressed as mean 6 SD (n=3). ND: not determined.
Fexinidazole was formulated as a suspension in 1% DMSO/99% methyl-cellulose
(1% w/v in water) and administered to female NMRI mice via gastric gavage at a
concentration of 25 mg/kg.
doi:10.1371/journal.pntd.0000923.t005
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metabolites were measured and showed that fexinidazole was
adequately absorbed, resulting in a significant and prolonged
exposure of especially fexinidazole sulfoxide and sulfone (data up to
14 days of treatment in rats and dogs is shown in Tables 6 and 7).
Preliminary studies on the potential effects of fexinidazole on
embryo-foetal and early postnatal development were carried out in
pregnant rats and no adverse effects on embryos/foetuses,
parturition, and neonates were identified in dams. Further
standard development and reproductive toxicology (DART)
studies are currently ongoing to confirm and extend the
preliminary results.
Genotoxicity
Fexinidazole and its primary metabolites are nitroimidazoles
and, like many other nitroheterocyclic compounds, are potentially
mutagenic [48]. To evaluate bacterial mutagenicity, a standard
full Ames test was carried out on four strains of Salmonella
typhimurium, with and without rat liver microsomes [Dataset S18].
Fexinidazole elicited both frameshift and base substitution
mutations. However, this activity was significantly reduced or
abolished when nitroreductase-deficient Salmonella strains were
used for the assay (representative example shown in Figure 4). Rat
liver microsomes metabolise fexinidazole efficiently to the
sulfoxide metabolite under these experimental conditions (data
not shown), so mutagenicity of this metabolite is covered by the
above data. A separate Ames test of the sulfone metabolite gave
similar results to fexinidazole (data not shown). These data suggest
that the observed mutagenic activity is due to bacterial activation
of fexinidazole and its metabolites by nitroreductases, and is not an
inherent property of the compounds. A detailed analysis of
fexinidazole’s genotoxic potential on mammalian systems was
undertaken subsequently. First, genotoxicity in mammalian cells
was evaluated in an in vitro micronucleus test using human
peripheral lymphocytes [Dataset S19]. Fexinidazole did not
induce the formation of micronuclei, and thus no clastogenic
damage, either in the presence or absence of rat liver microsomal
Figure 3. Plasma concentrations of fexinidazole and its two main metabolites after 5 days of oral administration. 200 mg/kg
fexinidazole was administered to mice (n=3). Fexinidazole - open circles. Fexinidazole sulfoxide - open squares. Fexinidazole sulfone - open
diamonds.
doi:10.1371/journal.pntd.0000923.g003
Table 6. Rat plasma pharmacokinetic parameters for
fexinidazole and its metabolites after oral administration of
fexinidazole.
Dose (mg/kg/day)
(no. animals)
Sample
day
Cmax
(mg/mL)
Tmax
(h)
AUC0-t(last)
(mg?h/mL)
Plasma Fexinidazole
50 (6) 1 0.0960.07 1.4261.28 0.4760.34
14 0.1860.14 1.9261.20 0.8360.54
200 (6) 1 0.3860.28 1.9261.20 2.1661.34
14 0.5260.30 2.0861.11 3.0261.47
800 (6) 1 1.4860.71 1.5860.66 12.864.10
14 1.0260.87 3.1762.84 9.2965.20
Plasma Fexinidazole sulfoxide
50 (6) 1 2.7061.40 2.5061.22 15.469.28
14 5.2363.28 2.1760.98 29.8619.4
200 (6) 1 11.462.17 2.3360.82 85.9614.1
14 15.863.17 3.3361.03 118638.9
800 (6) 1 31.763.74 4.6761.63 4106101
14 25.068.99 2.6761.03 2776160
Plasma Fexinidazole sulfone
50 (6) 1 2.9262.26 7.3361.63 36.1628.6
14 6.3862.30 6.0062.19 89.6634.1
200 (6) 1 9.2961.75 8.0060.00 126617.5
14 20.262.42 7.3361.63 287636.5
800 (6) 1 42.6613.1 10.766.53 5746256
14 40.5613.0 6.6762.07 5436252
Data are expressed as mean 6 SD.
Cmax: maximum plasma drug concentration achieved. Tmax: time to reach Cmax.
AUC0-t(last): area under the plasma concentration time curve from initial to final
data point
doi:10.1371/journal.pntd.0000923.t006
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sulfone metabolite was also negative (data not shown). An in vivo
bone-marrow micronucleus test in mice administered high oral
doses of fexinidazole (up to 2 g/kg) confirmed the lack of
clastogenicity (Table 8B, Dataset S20), while plasma analysis of
these mice confirmed the exposure to fexinidazole and its two
major metabolites (data not shown). Finally, an ex vivo rat liver
unscheduled DNA synthesis study (Table 8C) confirmed the lack
of mammalian genotoxic activity for fexinidazole and its
metabolites [Dataset S21]. Taken together, these data support
the conclusion that fexinidazole does not pose a genotoxic risk to
patients.
No direct studies have been done on the mode of action of
fexinidazole. However, fexinidazole might act as a prodrug like
other 5-nitroimidazoles that are toxic to the parasites only after
bioreductive activation [54]. From studies of trypanosomes
resistant to the action of nitroimidazoles, it appears that these
parasites have bacterial-like nitroreductases, which can activate
nitroimidazole drugs into reactive intermediates that in turn cause
cellular damage [55]. Fexinidazole and the sulfoxide and sulfone
metabolites were shown to have a low single electron redox
potentials being 2511 mV, 2493 mV, and 2488 mV, respec-
tively. In the same study, the single electron redox potential of
metronidazole was 2516 mV, and of megazole was 2422 mV.
Discussion
This paper provides data showing that fexinidazole, a 2-
substituted 5-nitroimidazole identified among a series of existing
but long forgotten compounds, is a promising drug candidate for
HAT. A full set of preclinical studies have been conducted in
accordance with the regulatory requirements for pharmaceuticals
for human use, and fexinidazole has now successfully entered
phase I clinical trials. Fexinidazole is the first new drug candidate
in 30 years that is in clinical development for the advanced and
fatal stage of the disease (stage 2). In addition, being an oral drug
with the potential to be effective against both stage 1 and stage 2
HAT caused by T. b. gambiense and T. b. rhodesiense, it could become
the much needed breakthrough for HAT control by drastically
simplifying case management.
Fexinidazole has been shown to be selectively trypanocidal in
vitro on T. b. rhodesiense and T. b. gambiense parasites, both on
established laboratory strains and recent clinical isolates. Whilst in
vitro potency is modest, with IC50 values between 0.1 and 0.8 mg/
mL, a short course (4 or 5 days) of oral fexinidazole treatment is
curative in experimental mouse models of acute and chronic (stage
2) HAT at doses of 100–200 mg/kg/day. This would correspond
to a daily human equivalent dose (HED) for adults of 16 mg/kg
calculated based on body surface area [56]; however, more
detailed mouse pharmacodynamics studies are required together
with human PK data to be able to propose an effective therapeutic
dose, including duration. The experimental curative capacity of
fexinidazole is significant, as among the currently used drugs in the
clinic, only the highly toxic drug melarsoprol is curative in the
chronic mouse model which involves an established brain infection
that mimics stage 2 HAT. The observation that a single high dose
of fexinidazole was also partially curative in the acute model (data
Table 7. Dog plasma pharmacokinetic parameters for fexinidazole and its metabolites after oral administration of fexinidazole.
Dose (mg/kg/day) (no. animals)
Sample
day
Cmax
(mg/mL)
Tmax
(h)
AUC0-t(last)
(mg?h/mL)
Plasma Fexinidazole
50 (6) 1 0.0460.01 0.7560.61 0.1960.13
14 0.0360.01 1.0860.74 0.1560.13
200 (6) 1 0.0760.03 1.0060.55 0.4460.09
14 0.0860.01 1.5060.77 0.4560.14
800 (10) 1 0.1460.07 1.1560.47 0.8460.32
14 0.1460.05 1.2060.42 1.0560.30
Plasma Fexinidazole sulfoxide
50 (6) 1 3.7660.97 1.1760.41 19.665.68
14 2.9960.98 1.3360.52 13.665.99
200 (6) 1 8.1262.66 1.2560.61 51.4614.1
14 8.9962.83 2.0060.00 56.7616.6
800 (10) 1 14.563.95 1.5560.60 112631.8
14 13.664.09 1.6060.97 129639.8
Plasma Fexinidazole sulfone
50 (6) 1 8.5862.15 7.3361.63 146638.3
14 7.7862.89 5.3362.07 126659.1
200 (6) 1 17.662.46 12.768.91 348663.9
14 21.863.86 5.3362.07 384649.9
800 (10) 1 36.167.94 14.468.26 6606164
14 36.666.24 6.8061.93 6536118
Data are expressed as mean 6 SD.
Cmax: maximum plasma drug concentration achieved. Tmax: time to reach Cmax. AUC0-t(last): area under the plasma concentration time curve from initial to final data
point.
doi:10.1371/journal.pntd.0000923.t007
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which will be crucial to achieve an easy-to-use treatment for
remote and rural areas. While the predictive value of these murine
models in terms of the potential for curing stage 2 patients is not
fully established (only melarsoprol cures both), the demonstration
that a drug candidate can clear systemic trypanosome infections in
both the acute and chronic model, as well as clearing the brain
infection (no relapse in the chronic model), is widely considered as
the critical feature for a stage 2 HAT drug candidate.
It has been argued by some that obtaining data from other
animal models (rat, monkey) before moving into clinical
development is desirable. However, the urgency to find new drugs
for HAT combined with the lack of clinical candidates in the
pipeline warrants a bolder strategy. Moreover, as fexinidazole’s in
vivo efficacy is likely to depend on the combined exposure profile of
the parent drug and its two major metabolites, and knowing that
metabolism can vary between species, it is uncertain what can be
learned from additional animal disease models. Clearly, the critical
studies ahead to determine the curative potential of fexinidazole in
humans will be the human safety and PK studies in phase I, and
subsequently a proof-of-concept phase II study in patients.
Upon oral administration, fexinidazole is well absorbed and
rapidly metabolised into the sulfoxide and sulfone derivatives, both
of which have similar in vitro trypanocidal activity to the parent
compound. The excellent in vivo activity of fexinidazole when
administered orally is likely to be due to the cumulative exposure
to not one but three active compounds which distribute
throughout the body with different but overlapping kinetics, thus
Figure 4. Mutagenic activity of fexinidazole in the Ames test. Salmonella typhymurium strains TA98 (A) and TA100 (B) and their
nitroreductase-deficient variants TA98NR and TA100NR were used, in the presence and absence of metabolic activation (+/2 S9). A: Solid circles:
TA98 +S9; Open circles: TA98 -S9; Solid squares: TA98NR +S9; Open squares: TA98NR -S9; Negative control: Mean number of revertants per plate were
TA98 (2S9): 21; TA98 (+S9): 34; TA98NR (2S9): 29; TA98 (+S9): 18. B: Solid circles: TA100 +S9; Open circles: TA100 2S9; Solid squares: TA100NR +S9;
Open squares: TA100NR 2S9; Negative control: Mean number of revertants per plate were TA100 (2S9): 104; TA100 (+S9): 116; TA100NR (2S9): 90;
TA100NR (+S9): 111.
doi:10.1371/journal.pntd.0000923.g004
Fexinidazole for Sleeping Sickness
www.plosntds.org 11 December 2010 | Volume 4 | Issue 12 | e923ensuring effective exposure in both the systemic circulation and
the brain. In mice, rats and dogs, the half-life of fexinidazole after
oral treatment ranges from 1 h to 3 h, whilst the half-life of the
sulfoxide ranges from 2 h to 7 h and that of the sulfone can be up
to 24 h after dosing. As the in vitro intrinsic clearance rate by
human hepatocytes was lower than that of all other species tested,
it can be expected that the half-lives in humans will be even longer,
which further supports fexinidazole’s potential for a once per day
short-duration treatment schedule. On the other hand, a non-
linear dose-related absorption and consequent exposure was
observed in both rats and dogs (not done in mice). It will thus
be important to carefully analyse the dose-related PK of
fexinidazole and both metabolites after oral dosing in humans to
better predict the dose-response relationship.
While fexinidazole and the sulfoxide are metabolised by
multiple liver microsomal enzymes, suggesting a low risk for
drug-drug interactions, the metabolic route of the sulfone remains
to be established. No accumulation of either fexinidazole or the
primary metabolites was found in rats, and almost all drug-related
material was eliminated from the body within 48 h of oral dosing,
excreted mainly through faeces (59%) and urine (30%). The
distribution of fexinidazole and metabolites to the brain was
confirmed in mice and rats, and considering the lipophilicity of the
molecules (logDpH 7.4 2.83 [fexinidazole], 0.74 [sulfone], 0.52
[sulfoxide]), there is no reason to assume that the brain penetration
potential, critical for the efficacy in stage 2 HAT, would be
different in humans.
A full regulatory toxicology package has been conducted,
including safety pharmacology (respiratory, cardiovascular, and
general behaviour) and 4-weeks repeated-dose toxicokinetics
studies in the rat and the dog. Overall, fexinidazole was well
tolerated, with no specific issues of concern or target organs for
toxicity identified. Fexinidazole is positive in the classical in vitro
Ames test, but this effect is highly dependent on the presence of
bacterial nitroreductases. A carefully designed set of in vitro and in
vivo assays to detect possible signals of mammalian genotoxicity
remained negative.
While a clearly positive Ames test result has long been
considered a no-go for drug development (except for terminal
diseases) as it would indicate a possible risk for (human)
Table 8. Mutagenicity assessments of fexinidazole on mammalian cells.
A. In vitro micronucleus assay on human lymphocytes
Micronucleated binucleate cells (%)*
24-h PHA 48-h PHA
2S9 +S9 2S9 +S9
Fexinidazole dose (mg/mL)
0 0.75 0.40 1.1 0.90
20 0.50 0.50 1.1 0.60
40 0.40 0.55 0.60 1.20
80 0.70 0.75 0.90 0.40
**4-nitroquinoline N-oxide, 5.0 mg/mL 10.80 8.95
**Cyclophosphamide, 6.25 mg/mL 3.60 12.85
B. In vivo bone marrow micronucleus assay
Micronucleated PCE/1000 PCE/NCE
Fexinidazole dose (mg/kg)
0 1.0 0.75
500 1.4 0.82
1000 1.1 0.75
2000 1.8 0.89
**Cyclophosphamide, 4.0 mg/kg, 19.3 0.89
C Ex vivo unscheduled DNA synthesis assay on rat liver cells
Net nuclear grain count (2–4 h) Net nuclear grain count (12–14 h)
Fexinidazole dose (mg/kg)
0 0.2 0.6
500 0.0 0.4
1000 20.1 0.5
2000 20.4 0.2
**dimethylnitrosamine, 10 mg/kg 8.9
**2-acetamidofluorene, 75 mg/kg 9.8
*Relative Replication Index (RI: relative number of nuclei compared to controls) expressed as a %.
**positive control.
PCE: poly-chromatic erythrocyte. NCE: normo-chromatic erythrocyte. PHA: phytohemagglutinin.
doi:10.1371/journal.pntd.0000923.t008
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indication for mammalian genotoxicity, when bacterial specific
metabolism is involved, especially with certain compound classes
such as nitroimidazoles [57]. In fact several examples exist of
nitroaromatic drug candidates currently in development for
diseases requiring a much longer treatment than HAT, for
instance epilepsy and tuberculosis, in which either the positive
Ames test was not considered decisional to indicate a hazard to
patients or no bacterial mutagenicity was detected [58,59,60].
Instead, a carefully designed series of in vitro and in vivo mammalian
genotoxicity assays can be used to rule out the different possible
mechanisms of mutagenicity that would indicate a risk for
genotoxic-related carcinogenicity. The observation by us and
others that it is possible to select non-mammalian mutagenic
compounds within the nitroheterocycles family reopens the
potential for the further use of this family of compounds with
well-known anti-infective properties.
It is important to emphasize that the observed positive Ames
results in nitroreductase-containing tester strains in no way point
to a residual risk for carcinogenicity not captured by the detailed in
vitro and in vivo mammalian genotoxicity studies as performed with
fexinidazole. In contrast to what is often assumed, the in vitro
micronucleus test measuring chromosome damage is no less
sensitive as a screening test than the Ames test, even if it involves
larger scale genetic damage than bacterial point mutations [61].
Although there are a few documented examples of genotoxic
carcinogens that can induce chromosome damage but not
bacterial point mutations (e.g. arsenic), there are, to our
knowledge, no examples of genotoxic carcinogens that induce
bacterial point mutation but not chromosome damage.
It has also been argued that gut flora contains bacterial
nitroreductases, which could convert nitroaomatics into mutagenic
species, much like what is observed in the in vitro Ames test and
thus still present a genotoxic risk in vivo. A recent study of
AMP397, a nitroaromatic compound previously in clinical
development for epilepsy has attempted to address the issue of
potential generation of gut-bacteria derived mutagens [58]. This
compound has a similar profile to fexinidazole, with positive Ames
test results in standard strains and lack of activity in nitroreduc-
tase-deficient bacterial strains and in mammalian cell assays. Suter
et al. carried out a mutagenicity study of AMP397 in vivo in the
transgenic MutaMouse model using five daily doses at the
maximum tolerated dose and sampling at 3, 7 and 31 days after
treatment. No evidence of mutagenicity was seen in the colon or
liver. Likewise, a comet assay (measuring DNA strand breakage)
did not detect any genetic damage in the jejunum or liver of
treated rats after dosing the animals at a dose six times higher than
that possible in the mouse study. A radioactive DNA binding study
also failed to show any DNA binding in rat liver. Thus, if a
mutagenic metabolite was formed by intestinal bacteria, it is
unable to exert any genotoxic activity in adjacent intestinal tissue.
As the genetic toxicology profile of fexinidazole is the same as
AMP397 and the mechanism behind the bacterial specific
mutation seen is the same, there is no reason to expect a different
assessment regarding gut flora activation.
The mechanism of action of fexinidazole is not yet elucidated,
but likely involves bioreductive activation. Fexinidazole and the
sulfoxide and sulfone metabolites were shown to have a low single
electron redox potentials (ranging between 2511 and 2488 mV).
The nitroreductive enzymes present in mammalian cells can only
reduce compounds with relatively high redox potentials under
aerobic conditions. In contrast, bacterial nitroreductases such as
those in the Salmonella assay can act at much lower redox potentials
than equivalent mammalian systems. This gives a plausible
explanation for the positive results in the standard Ames test
and the reduced or abolished activity in nitroreductase-deficient
strains. In line with these observations, it is of interest to note that
the single electron redox potential of metronidazole was
2516 mV, while megazole’s is significantly higher at 2422 mV.
The rediscovery of fexinidazole as a drug candidate also shows
the success of the compound mining approach, during which a
careful investigation of existing compounds within a family of
known pharmacologically active compounds using state-of-the-art
science, has yielded a new drug candidate for clinical development
in a relatively short time. Starting the experimental work within
this limited set of existing compounds in 2005 (around 700
compounds tested, mainly parasitology and genotoxicity assays), a
preclinical candidate could be selected early 2007, and clinical
trials initiated in the second half of 2009. Compared to drug
discovery ‘‘from scratch’’, this represents a significant shortcut. It
also shows that it is worthwhile to dig into past research efforts to
find those potential drug candidates which are lingering in drawers
or on shelves. In particular in the context of non-profit drug
development such as for neglected diseases where the existence of
patents is not considered a prerequisite for development, this
compound mining strategy may be worthwhile to pursue more
vigorously.
Based on the data presented in this paper, fexinidazole has
entered clinical development, and a phase I trial is currently
ongoing to establish its PK and tolerability in healthy volunteers
from African origin (in a combined single ascending dose and
multiple ascending dose study) [62]. If well tolerated, fexinidazole
is expected to progress to phase II trials in patients with stage 2
HAT by the end of 2010.
If fexinidazole successfully completes clinical development, it
will represent a real breakthrough for the control of HAT in rural
Africa for several reasons. Fexinidazole would be the first oral drug
for stage 2 HAT, well tolerated and effective upon a short-course
treatment. Compared to the current options of either 10 days of
daily intravenous melarsoprol with its dreadful toxicity and waning
efficacy, the very complicated eflornithine monotherapy (56
infusions over 14 days), or even the recent improvement of NECT
(a combination therapy of 10 days oral nifurtimox and 7 days of 12
hourly eflornithine infusions), this would be ground-breaking.
Moreover, based on its simple chemistry and short synthesis,
fexinidazole is expected to be relatively cheap (certainly not more
than US$ 50 per treatment, likely significantly less). Furthermore,
stability data to date show that fexinidazole is very stable, which is
a good starting point for the development of a stable solid dosage
formulation for use in tropical climates. Finally and most
significantly, it could be the first treatment to be used for both
stage 1 and stage 2 HAT, thereby overturning the long-standing
but complicated diagnosis and treatment paradigm which includes
systematic lumbar punctures of every diagnosed patient to
determine which stage of the disease they are in before deciding
which treatment to prescribe (to avoid exposing a stage 1 patient to
the risks and burden of the stage 2 treatments).
A safe, effective, cheap and easy to use treatment for both stage
1 and 2 HAT, ideally in combination with an easy field diagnostic,
would make HAT control a realistic option for the future. In
contrast to the current diagnosis and treatments options which are
largely dependent on vertical HAT control approaches, this safe,
effective, easy to use stage 1+2 treatment could be integrated into
more horizontal approaches which are more likely to reach the
extremely poor and remote populations most affected by HAT.
Clearly, there are many hurdles to overcome before fexinidazole
can reach this target, but it surely is the most promising candidate
in many years. A concerted effort to progress fexinidazole
Fexinidazole for Sleeping Sickness
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warranted.
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